ArticleNature2024
Engineered CD47 protects T cells for enhanced antitumour immunity.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed.
- Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.Cancer research communications · 2025Trial
- Review
- Minor histocompatibility antigen TCR-T.Blood advances · 2026Review
- Fast-Food Component-Induced Epigenetic Modifications Modulate Immunotherapy in Metastatic Breast Cancer.ACS omega · 2026Article
- Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways.Apoptosis : an international journal on programmed cell death · 2026Article
- Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- CD47 and FOXP3Cancers · 2026Review
- Article
- CD163 Dominance Within Macrophages/Microglia Reflects a Favorable Prognosis in Patients With Glioblastoma.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026Article
- Mapping and engineering the human cell-cell interactome.Nature biotechnology · 2026Review
- A multidimensional pan-cancer analysis of CD47 and its role in promoting malignant phenotype in pancreatic adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.Smart molecules : open access · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.Journal of biomedical science · 2026Review
- Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.Cancer research · 2026Review
- In vivo CAR-T therapy: from molecular design to precision delivery.Journal of nanobiotechnology · 2026Review
- Engineered apoptotic vesicle mimetics with tunable "eat-me" signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors.Nature biotechnology · 2026Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
38 authors.
Sean A Yamada-Hunter *Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-4372-6587
Johanna Theruvath *Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Brianna J McIntoshCancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-3626-625X
Katherine A FreitasCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Frank LinCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0006-2967-9899
Molly T RadosevichCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Amaury LerusteCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6891-9588
Shaurya DhingraCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Naiara Martinez-VelezCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Peng XuCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Jing HuangCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Alberto DelaidelliBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Moksha H DesaiCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Zinaida GoodCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2343-5771
Roel PolakDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-7815-1202
Audre MayCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Louai LabaniehCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Jeremy BjelajacCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Tara MurtyCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Zach EhlingerCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Christopher W MountMedical Scientist Training Program, Stanford University, Stanford, CA, USA.
Yiyun ChenCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Sabine HeitzenederCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Kristopher D MarjonInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.
Allison BanuelosInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.
Omair KhanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.
Savannah L WassermanCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Jay Y SpiegelSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Sebastian Fernandez-PolDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Calvin J KuoDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7427-5985
Poul H SorensenBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Michelle MonjeMedical Scientist Training Program, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3547-237X
Robbie G MajznerStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6969-8011
Irving L WeissmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.ORCID 0000-0002-9077-7467
Bita SahafCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Elena SotilloCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3993-1932
Jennifer R CochranCancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6532-9873
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.ORCID 0000-0001-6323-4304
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8MUnderstanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MMedical Scientist Training ProgramT32GM145402 · NIGMS · STANFORD UNIVERSITY · PI Katrin F. Chua · 2022 to 2026
$10.0MStem Cell Biology, Cancer Stem Cell Biology, and Cancer ImmunotherapyR35CA220434 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2017 to 2023
$6.7MDeveloping Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline GliomasR01CA263500 · NCI · STANFORD UNIVERSITY · PI MACKALL, CRYSTAL, MONJE-DEISSEROTH, MICHELLE · 2021 to 2025
$3.3MNexTGen - STANFORDOT2CA278686 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2022 to 2026
$1.2MFour Laser, 18 Color Cell Sorter in the SSFFS10RR025518 · NCRR · STANFORD UNIVERSITY · PI HERZENBERG, LEONARD A · 2009 to 2009
$500kDefining the Role of Senescence in Limiting Therapeutic Efficacy of CAR T CellsF30CA271797 · NCI · STANFORD UNIVERSITY · PI MURTY, TARA · 2022 to 2025
$155kNCI NIH HHS F30 CA271797NCI NIH HHS OT2 CA278686NCI NIH HHS R01 CA263500NCI NIH HHS R35 CA220434NCI NIH HHS U54 CA232568NCRR NIH HHS S10 RR025518NIGMS NIH HHS T32 GM007365NIGMS NIH HHS T32 GM145402
Abstract
Adoptively transferred T cells and agents designed to block the CD47-SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system
Indexed as
CD47 AntigenImmunotherapy, AdoptiveNeoplasmsT-LymphocytesAnimalsAntibodiesAntigens, DifferentiationCell Line, TumorFemaleHumansMacrophage ActivationMacrophagesMaleMiceReceptors, Antigen, T-CellReceptors, Chimeric AntigenAntibodiesAntigens, DifferentiationCD47 AntigenCD47 protein, humanReceptors, Antigen, T-CellReceptors, Chimeric AntigenReceptors, ImmunologicSIRPA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.